Azar's Post-SOTU Statement Doesn't Mention Drug Prices, Right-To-Try

January 31, 2018
HHS Secretary Alex Azar issued a statement on the president's State of the Union speech that doesn't mention two of the three health care priorities Trump highlighted: bringing down high drug prices and enacting right-to-try policy. Both of those topics make drug companies uncomfortable, though drug companies have turned the debate over prices into a debate over health-plan rebates and hospital discounts. Trump implored Congress Tuesday (Jan 30) to pass federal right-to-try legislation to let terminally ill patients buy experimental...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.